Drug recall · May 6, 2020
Ceftazidime for Injection USP and Dextrose for Injection USP recall
Why: Failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 18018-3524, NDC 0264-3145-11
- Lots / codes
Lot #: H8J812, Exp. Date 31 JUL 2020
- Quantity
- 22,488 Duplex containers
- Company
- B. Braun Medical Inc, Irvine, CA
- Distribution
- Product was distributed nationwide within the United States.
- Initiated
- April 18, 2020 · Voluntary: Firm initiated
- Classified
- April 28, 2020
- Reported
- May 6, 2020
- Ended
- October 21, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ceftazidime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.